ABVC ABVC BioPharma, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ABVC matters now
ABVC BioPharma, Inc. (ABVC) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.45 with -28.22% on the session and $21.0M in market capitalization; recent performance reads 1-month +22.73% and YTD -36.62%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.6M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.1%.
The latest indexable market news headline is "Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.19
P/S
-24.58
EV/EBITDA
-2.42
DCF Value
$-0.09
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
1108.9%
Net Margin
1183.8%
ROE
-92.0%
ROA
-47.8%
ROIC
-56.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.6M | $-0.06 |
| Q4 2025 | $-796.0K | $-3.6M | $0.13 |
| FY 2025 | $0.00 | $-7.9M | $-0.39 |
| Q3 2025 | $0.00 | $-2.0M | $-0.05 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.57
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.